Description

Simple

A medication used to treat severe nearsightedness, a fungal infection in the eye, and the growth of new blood vessels in the eye.

Clinical

A benzoporphyrin derivative used to treat pathological myopia, ocular histoplasmosis, and choroidal neovascularization in macular degeneration.

Overview

Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.

Pharmacology

Indication

For the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis syndrome. Verteporfin can also be used to destroy tumors.

Pharmacodynamic

Verteporfin, otherwise known as benzoporphyrin derivative, is a medication used in conjunction with laser treatment to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration. Verteporfin accumulates in these abnormal blood vessels and,... Read more

Mechanism of action

Verteporfin is transported in the plasma primarily by lipoproteins. Once verteporfin is activated by light in the presence of oxygen, highly reactive, short-lived singlet oxygen and reactive oxygen radicals are generated. Light activation of verteporfin results in local damage to neovascular endothe... Read more

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Following intravenous infusion, verteporfin exhibits a bi-exponential elimination with a terminal elimination half-life of approximately 5-6 hours. Mild hepatic insufficiency increases half-life by approximately 20%.

Route of elimination

Elimination is by the fecal route, with less than 0.01% of the dose recovered in urine.

Toxicity

Overdose of drug and/or light in the treated eye may result in nonperfusion of normal retinal vessels with the possibility of severe decrease in vision that could be permanent. An overdose of drug will also result in the prolongation of the period during which the patient remains photosensitive to b... Read more

Adverse Effects

Contraindications

  • Route:
    • Intravenous
  • Regions: US
  • Patient Conditions:
      • Name: Porphyria
      • Drugbank Id: DBCOND0008396

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Verteporfin
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
Acetophenone
Acetophenone may increase the photosensitizing activities of Verteporfin.
Aminolevulinic acid
Aminolevulinic acid may increase the photosensitizing activities of Verteporfin.
Bergapten
Bergapten may increase the photosensitizing activities of Verteporfin.
Carprofen
Carprofen may increase the photosensitizing activities of Verteporfin.
Cyamemazine
Cyamemazine may increase the photosensitizing activities of Verteporfin.
Dihematoporphyrin ether
Dihematoporphyrin ether may increase the photosensitizing activities of Verteporfin.
Hexaminolevulinate
Hexaminolevulinate may increase the photosensitizing activities of Verteporfin.
Methoxsalen
Methoxsalen may increase the photosensitizing activities of Verteporfin.
Motexafin gadolinium
Motexafin gadolinium may increase the photosensitizing activities of Verteporfin.
Motexafin lutetium
Motexafin lutetium may increase the photosensitizing activities of Verteporfin.
Porfimer sodium
Verteporfin may increase the photosensitizing activities of Porfimer sodium.
Protoporphyrin
Protoporphyrin may increase the photosensitizing activities of Verteporfin.
Riboflavin
Riboflavin may increase the photosensitizing activities of Verteporfin.
Rostaporfin
Rostaporfin may increase the photosensitizing activities of Verteporfin.
Talaporfin
Talaporfin may increase the photosensitizing activities of Verteporfin.
Temoporfin
Temoporfin may increase the photosensitizing activities of Verteporfin.
Tiaprofenic acid
Tiaprofenic acid may increase the photosensitizing activities of Verteporfin.
Trioxsalen
Trioxsalen may increase the photosensitizing activities of Verteporfin.
2 References
  1. 1 . Chan WM, Lim TH, Pece A, Silva R, Yoshimura N: Verteporfin PDT for non-standard indications--a review of current literature. Graefes Arch Clin Exp Ophthalmol. 2010 May;248(5):613-26. doi: 10.1007/s00417-010-1307-z. Epub 2010 Feb 17.PubMed: 20162298
  2. 2 . Nowak-Sliwinska P, Karocki A, Elas M, Pawlak A, Stochel G, Urbanska K: Verteporfin, photofrin II, and merocyanine 540 as PDT photosensitizers against melanoma cells. Biochem Biophys Res Commun. 2006 Oct 20;349(2):549-55. Epub 2006 Aug 22.PubMed: 16945338